Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
NCT Number: NCT07084961
An open-label, single-center, crossover study to evaluate the impact of administration timing of TS-172 on the pharmacodynamics in healthy adult male subjects.
Looking for future studies?
Notify Me18 year–39 year
Male
Interventional
Phase 1
Tokyo, Japan
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral administration of TS-172 20 mg immediately before meal
Time frame: Up to 3 days postdose during each period
Time frame: Up to 3 days postdose during each period
Taisho Pharmaceutical Co., Ltd.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01909986
Healthy Adult Male Subjects
Nottingham, United Kingdom
View Trial DetailsNCT07515417
Dyssomnias, Health Adult Subjects
Mecca, Saudi Arabia
View Trial Details